1. RT CHARM confirms noninferiority of 16-fraction postmastectomy RT
Hypofractionated postmastectomy RT was noninferior to conventional treatment for reconstruction complications (12.3% vs 10.2%), supporting a shorter three-week course.
2. Proton therapy is associated with fewer second cancers in retinoblastoma survivors
At 15 years, in-field second malignancy incidence was 0% after proton RT versus 11.1% after photons, although the comparison was nonrandomized.
3. US consensus defines adjuvant RT indications for high-risk cutaneous SCC
Experts supported postoperative RT for unresectable positive margins and selected high-risk features, while elective nodal irradiation remained unresolved.
4. Five-fraction breast RT with boost shows low fibrosis but more pain
Five-year fibrosis was 8.9% after one-week breast RT with simultaneous boost, while breast pain was more frequent with boost in nonrandomized comparisons.
5. Updated toxicity model supports proton selection in lung cancer
A Dutch model predicted acute esophageal toxicity with AUC 0.75 and now informs proton selection, although clinical benefit remains unconfirmed.
That's the week. See you next Sunday.